氯沙坦钾联合黄葵胶囊治疗慢性肾小球肾炎的效果分析

The clinical efficacy analysis of losartan potassium combined with ambrette capsule in the treatment of chronic glomerulonephritis

目的观察氯沙坦钾联合黄葵胶囊治疗慢性肾小球肾炎(慢性肾炎)的临床效果。方法选取2012年1月至2015年12月本院诊治的142例慢性肾炎患者为研究对象,采用简单随机抽样法将其分为对照组和观察组,每组各71例。对照组患者采用氯沙坦钾单药治疗,观察组患者采用氯沙坦钾联合黄葵胶囊治疗。比较两组患者治疗后的临床效果及主要肾功能指标变化情况。结果治疗后,观察组患者24小时尿蛋白和血肌酐水平[(0.47±0.41)g,(77.52±10.38)mmol/L]均明显低于治疗前[(1.94±0.85)g,(84.02±12.47)mmol/L](P<0.05),且观察组患者24小时尿蛋白水平明显低于同期对照组[(0.96±0.52)g](P<0.05)。观察组患者治疗总有效率(94.37%)明显高于对照组(77.46%)(P<0.05)。两组患者不良反应发生率比较无显著差异(P>0.05)。结论氯沙坦钾联合黄葵胶囊治疗慢性肾炎有效率高,不良反应少。

Objective To observe the clinical effect oflosartan potassium combined with ambrette capsule in the treatment of chronic glomerulonephritis patients. Method 142 cases of chronic glomerulonephritis patients treated in our hospital from January 2012 to December 2015 were selected as research objects. They were divided into observation group and control group according to simple random sampling. Control group patients were treated with ambrette capsule, observation group patients were treated with losar~ potassium combined with ambrette capsule. The clinical effect and the changes of the main renal funetion indexes of the two groups were compared. Result After treatment, 24-hour urinary protein and serum creatinine levels of observation group patients [（0.47± 0.41） g, （77.52 ±10.38） mmol/L] was significantly lower than before treatment [（1.94 ±0.85） g, （84.02± 12.47） mmol/L] （P 〈 0.05）, and 24-hour urinary protein levels of observation group patients were lower than eontrol group [（0.96±0.52） g] （P 〈 0.05）. The total effective rate of observation group （94.37%） was significantly higher than that of control group （77.46%） （P 〈 0.05）. There was no significant difference in the incidence of adverse reactions between the two groups （P 〉 0.05）. Conclusion Losartan potassium combined with ambrette capsule has better curative effect for treating chronic glomerulonephritis, and fewer adverse reactions.